Kenya - English - Pharmacy and Poisons Board

recombinant human erythropoietin bp 4000 iu - injection - 4000 iu - antianemic preparations

Kenya - English - Pharmacy and Poisons Board

cadila pharmaceuticals (ea) ltd po box 79642-00200 nairobi - recombinant human erythropoietin bp 4000 iu - injection - 4000 iu - other antianemic preparations

Kenya - English - Pharmacy and Poisons Board

julphar pharmaceutical industries p.o box 997 ras al khaimah uae - recombinant human erythropoietin - injection - 2000i.u - other antianemic preparations

Kenya - English - Pharmacy and Poisons Board

julphar pharmaceuticals industries airport roaddigdaga p.o box 997 ras al khaimah - recombinant human erythropoietin - injection - 4000 i.u - other antianemic preparations

Kenya - English - Pharmacy and Poisons Board

ripple pharmaceuticals ltd p.o. box 10935-00100 - recombinant human erythropoietin alpha - injection - 4000 iu/0.1 ml - other antianemic preparations

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

recombinant) solution for injection 0.5ml pre-filled syringes (imported (united states) - recombinant haemagglutinin proteins - solution for injection

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

tenecteplase (recombinant tissue plasminogen activator (tnk-t-pa)

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

tenecteplase (recombinant tissue plasminogen activator (tnk-t-pa)

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

recombinant human erythropoietin

Israel - English - Ministry of Health

novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).